Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Cash: 2022-2025

Historic Change in Cash for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $6.6 million.

  • Centessa Pharmaceuticals' Change in Cash fell 97.55% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$344.2 million, marking a year-over-year decrease of 253.99%. This contributed to the annual value of $255.2 million for FY2024, which is 196.08% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Change in Cash of $6.6 million as of Q3 2025, which was up 110.78% from -$60.9 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Change in Cash high stood at $267.7 million for Q3 2024, and its period low was -$278.1 million during Q1 2025.
  • Over the past 3 years, Centessa Pharmaceuticals' median Change in Cash value was -$11.8 million (recorded in 2024), while the average stood at -$31.2 million.
  • In the last 5 years, Centessa Pharmaceuticals' Change in Cash spiked by 918.55% in 2024 and then tumbled by 2,733.93% in 2025.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Change in Cash stood at -$51.2 million in 2022, then increased by 15.10% to -$43.5 million in 2023, then spiked by 72.84% to -$11.8 million in 2024, then slumped by 97.55% to $6.6 million in 2025.
  • Its Change in Cash stands at $6.6 million for Q3 2025, versus -$60.9 million for Q2 2025 and -$278.1 million for Q1 2025.